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Background: The clipping of an artery supplying one of the two kidneys (2K1C) activates the renin-angiotensin
(Ang) system (RAS), resulting in hypertension and endothelial dysfunction. Recently, we demonstrated the intrarenal
beneficial effects of sildenafil on the high levels of Ang II and reactive oxygen species (ROS) and on high blood
pressure (BP) in 2K1C mice. Thus, in the present study, we tested the hypothesis that sildenafil improves endothelial
function in hypertensive 2K1C mice by improving the NO/ROS balance.
Methods: 2K1C hypertension was induced in C57BL/6 mice. Two weeks later, they were treated with sildenafil
(40 mg/kg/day, via oral) or vehicle for 2 weeks and compared with sham mice. At the end of the treatment, the
levels of plasma and intrarenal Ang peptides were measured. Endothelial function and ROS production were
assessed in mesenteric arterial bed (MAB).
Results: The 2K1C mice exhibited normal plasma levels of Ang I, II and 1–7, whereas the intrarenal Ang I and II
were increased (~35% and ~140%) compared with the Sham mice. Sildenafil normalized the intrarenal Ang I and II
and increased the plasma (~45%) and intrarenal (+15%) Ang 1–7. The 2K1C mice exhibited endothelial dysfunction,
primarily due to increased ROS and decreased NO productions by endothelial cells, which were ameliorated by
treatment with sildenafil.
Conclusion: These data suggest that the effects of sildenafil on endothelial dysfunction in 2K1C mice may be due
to interaction with RAS and restoring NO/ROS balance in the endothelial cells from MAB. Thus, sildenafil is a
promising candidate drug for the treatment of hypertension accompanied by endothelial dysfunction and kidney
disease.
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High blood pressure (BP) has become a health issue, with
a projected prevalence of about one third of the global
population worldwide by 2025 [1], and endothelial dys-
function is the hallmark of this condition [2]. Among the
different types of high BP, renovascular hypertension is an
important cause of secondary hypertension, which is char-
acterized by increased activation of the renin-angiotensin
system (RAS) [3-5]. The prevalence of renovascular* Correspondence: evasquez@pq.cnpq.br
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unless otherwise stated.hypertension has been estimated to be 5% of all hyperten-
sive individuals, but it can reach higher percentage de-
pending on the population’s characteristics, e.g., renal
artery stenosis can reach approximately 5% of persons
aged ≥ 65 years [6,7]. We have focused this study on this
secondary hypertension because these patients are highly
susceptible to develop resistance to conventional antihy-
pertensive drugs, increasing the morbidity and mortality
[4,8]. Thus, there is a need of studies to a better under-
standing and to develop new therapeutic approaches
against the progression of this disease.
Experimental renovascular hypertension was introduced
by Goldblatt in 1934 in dogs by performing unilateral clip-
ping of the renal artery, referred to as the two-kidney,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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came the main experimental model of 2K1C hypertension
in our and other laboratories [9-11]. However, genetic dis-
coveries and advances in molecular biotechnologies have
provided the opportunity to develop mouse models of car-
diovascular diseases, which has led to an increasing num-
ber of studies using this murine model of hypertension
[12-15]. Physiologically, it is well known that unilateral
renal artery stenosis reduces renal perfusion, which
activates the RAS [5]. Recently, this system has been
extended by the addition of a novel axis consisting of the
angiotensin-converting enzyme 2 (ACE2), the heptapep-
tide angiotensin (Ang) 1–7, and the G protein-coupled re-
ceptor Mas [16]. ACE2 converts the vasoconstrictive and
pro-oxidative peptide Ang II to Ang 1–7, which exerts
vasodilatory and antioxidant effects via its receptor, Mas
[16-19]. Although our laboratory analyzed some RAS pep-
tides during the development phase of 2K1C hypertension
in a murine model [3,20,21], in the present study, we ex-
tended the analysis of the Ang I, II and 1–7 levels in both
plasma and the stenotic kidney during the established
phase of renovascular hypertension.
Endothelial dysfunction is commonly observed in
chronic arterial hypertension and is characterized by im-
paired nitric oxide (NO) bioavailability and increased re-
active oxygen species (ROS) levels. In recent years, our
laboratory [15,22,23] and others [24,25] have investi-
gated microvascular endothelial dysfunction in various
models of cardiovascular disease, including the 2K1C
mouse model of hypertension, which has greatly contrib-
uted to our understanding of the relationship between
endogenous activation of the RAS and endothelial dys-
function in resistance arteries [15]. This model provides
suitable approach to evaluate the efficacy of new drugs
for the treatment of renovascular hypertension.
The phosphodiesterase 5 (PDE5) inhibitor sildenafil,
which increases the vascular signaling of the NO/cGMP
pathway [26,27], has successfully been used to treat
erectile dysfunction and pulmonary hypertension [28],
emerging as a promising alternative therapy for systemic
cardiovascular dysfunctions. Our laboratory has recently
shown that sildenafil was able to restore the endothelial
dysfunction and blood mononuclear and liver cell DNA
damage, which accompany atherosclerosis [27,29].
Moreover, Dias et al. [21] recently reported that sildena-
fil ameliorates the oxidative damage to the stenotic kid-
ney and reduces the intrarenal levels of Ang II in the
2K1C mouse.
Therefore, the present study was designed to evaluate
the effect of chronic treatment with sildenafil on high BP,
the levels of peptide components of the RAS and vascular
function in the hypertensive 2K1C mouse. We hypothe-
sized that sildenafil reduces the deleterious effects of Ang
II, increases the levels of the counterbalancing peptideAng 1–7 and restores the endothelial function of resist-
ance vessels in hypertensive 2K1C mice. The confirmation
of this hypothesis may provide a novel pharmacological




Experiments were performed in male wild-type mice
(C57BL/6) that weighed 23 g on average (10-week-old).
Mice were bred and maintained in the Laboratory of
Translational Physiology animal facility (Vitoria, ES,
Brazil) and were fed with a standard chow diet and re-
ceived water ad libitum. Animals were housed in individ-
ual plastic cages with automatic controlled temperature
(22°C) and humidity (60%) and were exposed to a 12/12 h
light–dark cycle. All of the experimental procedures were
performed in accordance with the National Institutes of
Health (NIH) guidelines, and the study protocols were ap-
proved by the Institutional Animal Care and Use Commit-
tee (CEUA-EMESCAM Protocol # 02/2013).
Induction of 2K1C renovascular hypertension and treatment
The 2K1C Ang-dependent hypertension was induced as
previously described [3,12,15,21,30]. Briefly, animals
were anesthetized (91/9.1 mg/kg ketamine/xylazine, i.p.).
The left renal artery was exposed through a retroperi-
toneal flank incision and carefully isolated from the renal
vein, nerves, and connective tissues. Using an ophthal-
mic surgical microscope (Opto Eletronica SA, model SM
2002, Belo Horizonte, MG, Brazil), a U-shaped stainless
steel clip with a 0.12 mm wide opening was placed
around the renal artery near the abdominal aorta, which
decreased renal perfusion [31]. Two weeks after surgery,
animals were divided into two groups (8 to 10 animals
per group): renovascular hypertensive mice treated with
vehicle (2K1C) and hypertensive mice treated with
40 mg/kg/day of the PDE5-inhibitor sildenafil (Viagra®,
Pfizer) for 2 weeks by oral gavage (2K1C-sildenafil). Sham-
operated mice were used as a normotensive control group.
The effectiveness of this sildenafil dose [32] was previously
demonstrated in studies on endothelial dysfunction and
DNA damage in our laboratory [21,27,29]. The outcomes
were examined 28 days after induction of hypertension.
Hemodynamic measurements
Twenty six days after 2K1C procedure or sham operation,
mice were anesthetized with a combination of ketamine/
xylazine (91/9.1 mg/kg, i.p.) and a catheter (0.040 mm
outer × 0.025 mm inner diameters, MicroRenathane,
Braintree Science, Massachusetts, USA) was inserted into
the right carotid artery for the measurement of mean ar-
terial pressure (MAP) and heart rate (HR) recordings. The
free catheter end was tunneled under the skin of the back
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ments were performed in conscious, freely moving mice in
their own cages, two days after catheter placement, as
already validated as a sufficient period for complete recov-
ery from surgery by others [33] and standardized in our la-
boratory [3,13-15]. For the MAP and HR recordings, the
arterial catheter was plugged into a disposable BP trans-
ducer (Cobe Laboratories, Colorado, USA) connected to a
pressure processor amplifier and data-acquisition system
(MP100, Biopac Systems, California, USA). At the be-
ginning of the experimental session, a period of ap-
proximately 30 min was allowed for stabilization of
cardiovascular parameters before the measurement of
basal MAP and HR values in conscious mice (Acknow-
ledge software, Biopac Systems).
Assessment of endothelial function
At the end of the treatment, animals were anesthetized
using sodium pentobarbital (50 mg/kg, i.p.), and the
mesenteric arterial bed (MAB) was isolated and prepared
for vascular studies. The superior mesenteric artery was
cannulated. Then, the MAB was transferred to a 37°C
chamber and was perfused using a peristaltic pump
(Peri-Star Pro 4-channel pump, WPI, Lu Jia Zui District,
Shangai, China) at a constant flow rate (3 mL/min) with
oxygenated (95% O2 - 5% CO2 mixture) physiological salt
solution (in mmol/L: 130 NaCl, 4.7 KCl, 1.6 CaCl2•2H2O,
1.18 KH2PO4, 4.7 MgSO4•7H2O, 14.9 NaHCO3, 0.026
EDTA, 11.1 glucose, pH 7.4). The perfusion pressure was
monitored using a T-tube inserted between the pump and
the inflow cannula that was connected to a pressure trans-
ducer and a data acquisition system (Biopac Systems).
Then, dose–response curves of acetylcholine (ACh, 3 ×
10−7 to 3 × 10−2 M) and sodium nitroprusside (SNP, 3 ×
10−7 to 3 × 10−2 M) were generated in the isolated MABs.
The vascular responses were evaluated based on the
changes in the perfusion pressure and the vasodilator re-
sponses to ACh and SNP, which were calculated as a per-
centage of the pre-contraction induced by norepinephrine
(NE, 9.8 × 10−6 M). To assess the mechanisms underlying
the vascular effect of ACh dose–response curves were gen-
erated in separate preparations containing an intact endo-
thelium and using specific blocker agents: (a) the
nonselective NO synthase (NOS) inhibitor N-nitro-L-argin-
ine methyl ester (L-NAME, 10−4 M), (b) the nonselective
inhibitor of cyclooxygenases 1 and 2 (Cox1 and Cox2)
indomethacin (10−5 M) or (c) the NAD(P)H oxidase inhibi-
tor apocynin (30 μM). The relaxation responses to ACh
were expressed as the percentage of dilation relative to the
maximal pre-contraction level. For each curve, the max-
imum effect (Rmax) and the log of the concentration of the
agonist that produced half of Rmax (log EC50) were calcu-
lated via nonlinear regression analysis. The sensitivities of
the agonists were expressed as pEC50 (−log EC50). Thedifference in the area under the curve (Δ AUC) for each of
the responses of the MAB to ACh in the presence of each
inhibitor were calculated, and these results were expressed
in arbitrary units (a.u.).
Measurements of the angiotensin peptide levels
The plasma and intrarenal levels of Ang I, II and 1–7 were
analyzed via high performance liquid chromatography
(HPLC), as previously reported [20,21,30]. For this ana-
lysis, blood was collected in the presence of EDTA and a
protease inhibitor cocktail (Product # P2714, Sigma-
Aldrich), and after centrifugation (9.5 g, for 20 min) using
a refrigerated centrifuge (4°C), plasma was collected for
further analysis. The Ang peptides were extracted using
Oasis C18 columns previously activated with methanol
(5 mL), tetrahydrofuran (5 mL), hexane (5 mL) and water
(10 mL). After activation, the samples were eluted in etha-
nol/acetic acid/water at proportions 90% - 4% - 6%. The
eluates were dried, re-dissolved in 500 μL of mobile phase
A (5% acetonitrile in 0.1% phosphoric acid) and filtered
for analysis by HPLC. The Ang peptides in each sample
were separated using a reverse-phase ODS Aquapore 300
(250 × 4.6 mm) HPLC column with a particle size of 7 μm
(Perkin-Elmer’s Brownlee Columns, Norwalk, USA) using
a 5–35% gradient of mobile phase B: 95% acetonitrile in
0.1% phosphoric acid at a flow of 1.5 mL/min for 40 min.
The Ang peptides were identified by comparing them with
the retention times and peak heights of standard peptides.
For renal analysis of the Ang peptides, they were ex-
tracted from kidney homogenates and purified as per-
formed on plasma samples. The subsequent steps, from
the activation step to the HPLC analysis step using the
reverse-phase column, the procedures were the same as
those for plasma sample analysis. The Ang peptides were
identified based on the retention time (<6%) and peak
height (<5%) of standard Ang peptides and were normal-
ized according to the kidney weight.
Isolation and identification of endothelial cells from MAB
At the end of the treatment, animals were anesthetized
with sodium pentobarbital (50 mg/kg, i.p.), the midline of
the abdomen was incised and the MAB was isolated,
minced and digested with type II collagenase (1000 U/mL)
at 37°C for 60 min at constant agitation. The cellular di-
gest was filtered through a sterile 70-μm nylon mesh to re-
move cell debris, centrifuged at 400 g for 10 min, and
washed twice in PBS. The cell pellet was resuspended in
freezing solution and stored at −80°C for further analysis.
For flow cytometry analysis, the samples were thawed
using a heated orbital shaker at 37°C and immediately
transferred to a round-bottom tube, in which DMEM con-
taining 20% FBS was added in a drop wise fashion during
a gentle agitation. The presence of endothelial cells in
MAB digest was confirmed using an APC-conjugated
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After thawed, MAB digest cell samples were resuspended
at a concentration of 1 × 105 cells/mL in PBS and incu-
bated with 5 μL of CD31-APC for 20 min in the dark and
at room temperature. In the flow cytometry analysis, a
APC-conjugated rat IgG2a was used as an isotype-specific
control to set the threshold values. From each sample,
100,000 events have been generated by a FACSCanto II
flow cytometer (Becton Dickinson - BD, San Juan, CA,
USA) using an appropriated filter for APC (660 nm).
Measurement of endothelium ROS
The ROS analysis was performed by flow cytometry using
dihydroethidium (DHE), diaminofluorescein (DAF) and
hydroxyphenyl fluorescein (HPF) to detect intracellular
•O2
−, NO and •ONOO−, respectively, as previously
described [21,31]. Briefly, 160 mM of DHE or 10 μM of
HPF or 2 μM of DAF was added to the cell suspension
(106 cells) and incubated at 37°C for 30 min (DHE and
HPF) or 180 min (DAF) in the dark. For positive control,
samples were treated for 5 min with 50 mM H2O2 and/or
100 μM of SNP to create oxidative stress without being
toxic to the cells, whereas for negative control, the cells
were incubated with ethanol. Cells were then washed,
resuspended in PBS and kept on ice for immediate detec-
tion by flow cytometry (BD). For quantification of DHE,
DAF and HPF fluorescence, 100,000 events were acquired
and data were analyzed using the FACSDiva software (BD).
Statistical analysis
The values are expressed as the means ± S.E.M. The
Kolmogorov-Smirnov test indicated that the variables dis-
played a normal (Gaussian) distribution. Statistical com-
parisons between more than two means were performed
using one-way or two-way analysis of variance (ANOVA)
followed by Bonferroni’s post hoc test. The statistical ana-
lyses were performed using Prism software (Prism 6,
GraphPad Software, Inc., San Diego, CA, USA). A value of
p < 0.05 was considered to be statistically significant.Figure 1 Effects of sildenafil on hemodynamics. Resting arterial
blood pressure (A) and heart rate (B) in 2K1C hypertensive mice
four weeks after renal artery clipping compared with non-treated
mice 2K1C and Sham mice. Values are means±SEM for n = 6 to 8
animals per group. *p < 0.05 and **p < 0.01, one-way ANOVA.Results
Body and kidney weights
The initial body weight was similar between the groups.
By the end of the experiments, only the non-treated 2K1C
group displayed reduced body weight (−7%) compared
with the Sham group (26±0.5 g) and the 2K1C group
treated with sildenafil (25±0.3 g). Twenty-eight days after
surgery, the left clipped kidney atrophied (29±2.6 mg, p <
0.05), whereas the right non-clipped kidney displayed
compensatory hypertrophy (49±0.3 mg, p < 0.05) in the
non-treated 2K1C mice compared with the Sham mice
(42±2.0 and 45±1.2 mg, respectively). As previously re-
ported by our laboratory [21], sildenafil not only reducedthe renal atrophy of the clipped kidney (38±0.7 mg, p <
0.05) but also attenuated the compensatory hypertrophy
of the contralateral kidney (43±1.2 mg, p < 0.05).
Blood pressure and heart rate
The average values of resting BP and HR measured in
conscious animals 28 days after renal artery clipping
are summarized in Figure 1. As expected, the 2K1C
mice exhibited a higher BP (26%, p < 0.01) than the sham
mice (104±2 mmHg), and sildenafil treatment reduced
these levels to values similar to those of the Sham mice
(Figure 1A). The resting HR of the 2K1C mice was signifi-
cantly higher (+14%, p < 0.05) than that of the Sham mice
(Sham: 451±18 bpm), but no significant difference was de-
tected after sildenafil treatment (Figure 1B).
Plasma angiotensin measurements
Figure 2 shows the average values of the levels of the
plasma (bar graphs A, C and E) and intrarenal (bar graphs
B, D and F) Ang peptides 28 days after the induction of
hypertension by clipping the renal artery. Analysis of the
plasma levels of Ang revealed normal levels of Ang I, a
Figure 2 Effect of sildenafil on angiotensin peptides. Plasma and intrarenal levels of angiotensin I (A and B), II (C and D) and 1–7 (E and F)
in 2K1C hypertensive mice and 2K1C mice treated with sildenafil compared with the Sham group value (100%). Values are means±SEM for n = 5
to 8 animals per group. *p < 0.05 and **p < 0.01, one-way ANOVA.
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normal levels of Ang 1–7 in the hypertensive 2K1C mice
compared to the Sham mice (Figure 2A, C and E). The
2K1C mice treated with sildenafil exhibited plasma levels
of Ang I and II that were similar to those of the sham
mice. However, sildenafil treatment induced a marked in-
crease (46%, p < 0.01) in the plasma levels of Ang 1–7 in
the hypertensive 2K1C mice (Figure 2E). The intrarenal
levels of Ang I were slightly higher (34%, p < 0.05) and
those of Ang II were markedly higher (143%, p < 0.01) in
the hypertensive 2K1C mice compared with the Sham mice
(Figure 2B and D). However, sildenafil treatment abolished
these increases in the intrarenal levels of Ang I and II
(Figure 2B and D) and significantly increased the normal
levels of intrarenal Ang 1–7 (15%, p < 0.01) (Figure 2F).
Vascular function
The endothelium-dependent relaxation in response to ACh
at a constant flow rate in a perfused MAB from each group
is shown in Figure 3. The dose–response curves clearlyshowed a marked impairment of vascular vasodilation in
response to ACh in the non-treated hypertensive 2K1C
mice compared with the Sham mice (Figure 3A), but this
difference was abolished in the 2K1C group chronically
treated with sildenafil (Figure 3B). The calculation of the
AUCs revealed a significant reduction in the AUC of the
hypertensive 2K1C group (~40%, p < 0.01) compared with
the sham group. Treatment with sildenafil significantly
recovered the AUC to 88% of that of the sham group
(Figure 3C). The maximum vascular response (Rmax) was
significantly decreased in the MABs from non-treated
2K1C mice (−36%, p < 0.01) but not in those from hyper-
tensive 2K1C mice treated with sildenafil (−11%, p > 0.05),
compared to those from the Sham mice (mean of 75±3%,
p < 0.01) (Figure 3D). No significant differences were de-
tected in the pEC50 between the groups (Figure 3E). In an
independent protocol, we examined the functionality of
the endothelium-independent vasodilation using NO
donor SNP. No significant differences were detected
between the three groups of animals (data not shown).
Figure 3 Effect of sildenafil treatment on the endothelial function. Acetylcholine-induced relaxation of mesenteric arterial bed preconstricted
using norepinephrine, comparing 2K1C mice treated with sildenafil with non-treated 2K1C hypertensive and sham control mice (A and B). Bar
graphs show the area under the curve (C), the maximum relaxation (Rmax) (D) and the sensitivity (pEC50) (E). Values are the means±SEM for
8–10 animals per group. **p < 0.01, one- (C, D and E) and two-way (A and B) ANOVA.
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pathologies is typically associated with 1) decreased NO
production and/or increased metabolism, 2) decreased
prostacyclin (PGI2) synthesis, 3) increased production
of contractile cyclooxygenase-derived prostanoids, 4) al-
tered endothelium-dependent hyperpolarizing factor
(EDHF) levels and 5) increased production of ROS
[15,22], we designed additional experiments to examine
various molecular pathways.
The participation of ROS in the relaxation response to
ACh was assessed via pre-incubation of the MABs in
apocynin, an inhibitor of NADPH. Figure 4 summarizes
the dose–response curves in response to ACh for the three
groups. As expected, in sham mice (Figure 4A and D),
apocynin blockade did not induce a significant change in
the ΔAUC (+13 a.u., p > 0.05). In contrast, the hypertensive
2K1C mice exhibited an improved vasodilation response to
ACh (Figure 4B), as indicated by an increase in the ΔAUC
(+65 a.u., p < 0.01, Figure 4D). In the hypertensive 2K1C
mice treated with sildenafil, in which the dose–response
curve in response to ACh in the absence of apocynin treat-
ment was similar to that of the Sham mice (Figure 4C),
apocynin treatment did not induce a significant change in
the ΔAUC (Figure 4D). Similarly, preincubation of theMABs with apocynin did not induce a significant change
in the Rmax to ACh in Sham mice (from 73±5% to 80±2%,
Δ + 10%, p > 0.05) or in 2K1C mice treated with sildenafil
(from 75±2% to 69±3%, Δ-8%, p > 0.05). In contrast, in
2K1C hypertensive mice, apocynin treatment induced an
improvement in the Rmax (from 49±2% to 64±3%, Δ +
30%, p < 0.01) (Figure 4E). However, there was no signifi-
cant difference in the sensitivity (pEC50) between the three
groups of animals (Figure 4F). These data indicate that in-
creased ROS production significantly contributes to the
impairment of endothelium-dependent relaxation in
MABs from hypertensive 2K1C mice and that sildenafil
treatment restores the normal oxidative balance in these
animals.
Figure 5 summarizes the data of the vasodilation dose–
response curves in response to ACh under the conditions
of NOS blockade using L-NAME in MABs from the three
groups of animals. Under L-NAME-mediated NOS block-
ade, the ΔAUC was decreased in Sham mice (−77±5 a.u.,
Figure 5A and D) and mainly in the hypertensive 2K1C
mice (−26±4 a.u., Figure 5B and D), and these alterations
were ameliorated by treatment of the 2K1C mice with
sildenafil (−93±4 a.u., Figure 5C and E, p < 0.01). The
dose–response curves in response to ACh in the presence
Figure 4 Contribution of reactive oxygen species to the endothelial dysfunction. Data show the effect of the blockade of NAD(P)H oxidase
activity with apocynin on the dose–response curve to acetylcholine (ACh) in Sham (A), non-treated 2K1C (B) and 2K1C mice treated with sildenafil (C)
mice. Bar graphs show the area under the curve (D), maximum response (E) and the sensitivity (pEC50) (E and F, gray color) and the relative changes
induced by apocynin (E and F, blue color) in the groups of animals. Values are the means±SEM for 8–10 animals per group. **p < 0.01 (gray bars) and
##p < 0.01 (apocynin effect, green bars), one- (D, E and F) and two-way (A, B and C) ANOVA.
Figure 5 Contribution of nitric oxide to the endothelial function. Dose–response relaxation curves to acetylcholine (ACh) in Sham (A),
non-treated 2K1C hypertensive (B) and sildenafil-treated 2K1C (C) mice with and without blockade of nitric oxide synthase (NOS) with L-NAME.
Bar graphs show the area under the curve derived from the dose–response curves to ACh (D), the maximum response (Rmax) (E) and pEC50 (F).
Values are the means±SEM. **p < 0.01 and #p < 0.05 compared to the group indicated by the line; two-way ANOVA (A, B and C) and one-way
ANOVA (D, E and F).
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in the Sham mice (from 72±5% to 53±3%, Δ-19%, p <
0.01, Figure 5E). In the non-treated 2K1C mice, in which
the vasorelaxation response to ACh was already markedly
impaired, L-NAME blockade caused a smaller but signifi-
cant decrease in the perfusion pressure, as Rmax was fur-
ther decreased (from 45±4% to 31±2%, Δ-14%, p < 0.01,
Figure 5E). In the 2K1C mice treated with sildenafil, the
dose–response curves in response to ACh in the pres-
ence of L-NAME displayed a similar alteration in the
perfusion pressure (from 73±3% to 47±4%, Δ-26%, p <
0.01, Figure 5E) to that of the Sham mice. No significant
difference in the pEC50 was detected between the three
groups (Figure 5F). Taken together, these results indi-
cate that treatment of hypertensive 2K1C mice with sil-
denafil restores the decreased NO bioavailability in the
MAB to that of normotensive Sham mice.
To indirectly quantify the contribution of prostanoids
and other pathways not involving NO or prostanoids to
the relaxation response induced by ACh, we designed an
experiment in which two inhibitors, L-NAME and indo-
methacin, were applied (Figure 6). Thus, the difference
in the AUC between treatment with both inhibitors and
treatment with L-NAME alone indicates the contribu-
tion of the prostanoids pathway (Figure 6F), and differ-
ence between the AUC under control conditions and the
AUC in the presence of both inhibitors indicates the
contribution of EDHF and other unidentified vasodila-
tory pathways (Figure 6E). The dose–response curves in
response to ACh under in the presence of both inhibi-
tors were significantly shifted upward (reduced perfusion
pressure, i.e., reduced vasodilation) in all three groups of
animals, although to a lesser extent in the hypertensive
2K1C group (Figure 6B) and to a greater extent in the
2K1C group treated with sildenafil (Figure 6C) com-
pared with the Sham group (Figure 6A). The AUC (be-
fore - after treatment with both inhibitors), as shown in
Figure 6D), was significantly reduced in the Sham mice
(−122 a.u., p < 0.01) and was markedly increased in the
hypertensive 2K1C mice (50%, p < 0.01), but recovered by
treatment with sildenafil (−133 a.u., p < 0.01). The contri-
bution of prostanoids to the change in the AUC was signifi-
cantly reduced in the hypertensive 2K1C mice (47%, p <
0.01) compared with the Sham mice (45±4 a.u.); sildenafil
treatment restored these values to control levels (40±5 a.u.)
(Figure 6F). The contribution of EDHF and other un-
identified pathways was greater than that of the prosta-
noids pathways, as indicated by the average values
shown in Figure 6E. The ΔAUC associated with EDHF
and other unidentified vasodilation pathways was sig-
nificantly reduced in the hypertensive 2K1C mice (30%,
p < 0.01) compared with the Sham mice (Figure 6E).
This difference was abolished by treatment with silden-
afil. The Rmax in the presence of both inhibitors wassignificantly decreased in all three groups (Figure 6G),
although to a lesser extent in the hypertensive 2K1C group
(from 42±4% to 31±2.0%, Δ-11%, p < 0.01) and to a
greater extent in the 2K1C group treated with sildenafil
(from 71±3% to 36±5%, Δ-35%, p < 0.01) compared with
the Sham group (from 76±5% to 48±4%, Δ-38%, p < 0.01).
The sensitivity (pEC50) was similar between the three
groups both before and after treatment with both inhibi-
tors (between groups), but in the 2K1C mice treated with
sildenafil, treatment with both inhibitors induced a signifi-
cant decrease (−20%, p < 0.05, Figure 6H).
The bar graph in Figure 7, which was generated using the
AUCs from dose–response curves to ACh from Figures 3,
4, 5 and 6, displays the relative contribution of each mo-
lecular pathway to vasodilatory process (difference between
the total AUC and the AUC after treatment with both L-
NAME and indomethacin) and the opposing effect of
the ROS pathway. The total AUC of the Sham group
(275±13 a.u.) was considered as 100% and was used as
the reference value for comparisons with the non-
treated 2K1C group (169±11 a.u.) and the 2K1C group
treated with sildenafil (263±15 a.u.). As shown, the con-
tribution of the NO/cGMP pathway was markedly im-
paired in the hypertensive 2K1C mice (34%), which
were recovered by sildenafil treatment (121%). The
prostanoids/cAMP pathway, which includes PGI2 and
other vasodilatory eicosanoids, was also substantially
impaired in the hypertensive 2K1C mice (53%), and sil-
denafil treatment attenuated this impairment (89%).
The residual area of the total AUC after treatment with
both inhibitors (L-NAME and indomethacin) corre-
sponds to the contribution of other known vasodilatory
factors, such as EDHF/K+ channels, and, in our opinion, it
could also include the Ang 1–7; this pathway was slightly
attenuated (78%) and was incompletely restored by silden-
afil treatment (86%). The ROS levels were markedly in-
creased in the hypertensive 2K1C mice (500%), and we
found that its inhibitory effect on the vasodilation process
was alleviated by sildenafil treatment (23%).
Flow cytometry analysis of oxidative stress in endothelial
cells from MAB
Intracellular •O2
−, •ONOO− and NO in endothelial cells
were quantified by flow cytometry through DHE, HPF and
DAF staining. Top panels of Figure 8 are typical histo-
grams showing a rightward-shift in the log of DHE and
HPF fluorescence in 2K1C hypertensive mice compared
with Sham mice and contrasting with a leftward-shift ob-
served in 2K1C animals treated with sildenafil. On the
other hand, the typical histogram of NO production of the
2K1C mouse treated with sildenafil, showed a rightward-
shift in the log of DAF fluorescence when compared with
the 2K1C hypertensive mouse. As summarized in the bar
graphs (Figure 8), endothelial cells isolated from MAB of
Figure 6 Contribution of prostanoids and other relaxing pathways to the endothelial dysfunction. A: dose–response relaxation curves to
acetylcholine (ACh) in Sham (A), non-treated 2K1C hypertensive (B) and sildenafil-treated 2K1C (C) mice. Dose–response curves to ACh were
obtained with and without the double blockade of NOS with L-NAME and of cyclooxygenases with indomethacin. Bar graphs show the area
under the curve (AUC) after the double blockade (D), the total AUC minus the AUC after the double blockade (contribution of EDHF and other
pathways, E) and the AUC derived from the AUC under double blockade minus the AUC under the L-NAME blockade (prostanoids pathway, F).
Graphs G and H show the effects of indomethacin on the maximum relaxation (Rmax, G) and sensitivity (pEC50, H) and on these two parameters.
Values are the means±SEM for 8 to 10 animals per group. *p < 0.05, #p < 0.05, **p < 0.01and ##p < 0.01, compared with the group indicated by
the line; two-way ANOVA (A, B and C) and one-way ANOVA (D-H).
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−
and •ONOO− levels (41% and 76%, respectively, p <
0.05) when compared with the levels of Sham mice
(1252±81 and 1524±25 a.u., respectively). However, the
chronic treatment of 2K1C mice with sildenafil was
able to decrease the production of •O2
− and •ONOO−
to levels (1266±25 and 1518±40 a.u., respectively, p <
0.05) similar to that observed in the Sham group. Add-
itionally, sildenafil treatment of 2K1C mice restored
the NO levels (6310±172 a.u., p < 0.05) when com-
pared with Sham (6273±218 a.u.) and the non-treated
2K1C mice (1242±25 a.u.).Discussion
Previous results from our laboratory [21] demonstrated
by the first time that sildenafil repaired the hypoperfused
kidney injury in 2K1C hypertensive mice by activation of
the NO-mediated pathway. This pleiotropic protective
role of sildenafil led us to investigate other additional
beneficial effects of this drug on the systemic RAS and
resistance vasculature in this model of hypertension.
Our primary finding was that chronic treatment of these
animals with this selective PDE5 inhibitor sildenafil re-
stored the levels of BP and vascular relaxation to those
of normotensive sham mice. Moreover, the present study
Figure 7 Schematic diagram illustrating the individual contribution of each endothelial pathway to the endothelial function in the
RAS-dependent renovascular hypertension. Data show percentage of changes in the area under the curve (AUC) in relation to the Sham
group (100%) and was derived from the difference in the area under the dose–response curve to acetylcholine (Figures 3, 4, 5 and 6) before and
after the blockade of the molecular pathways; endothelial nitric oxide (NO) synthase (with L-NAME), cyclooxygenases (Cox)/prostanoids such
as prostacyclin (PGI2) and other eicosanoids (with indomethacin), reactive oxygen species (ROS)/NADPH oxidase (with apocynin) and endothelial-
derived hyperpolarizing factor (EDHF) (residual response after double blockade with L-NAME and indomethacin).
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appear to be mediated by decreasing the levels of the vaso-
constrictive and pro-oxidant peptide Ang II and increasing
the levels of its physiological antagonist Ang 1–7.
A recent work from Navar’s group and our collabor-
ator Casarini’s group [34] revealed that the maintenance
of high blood pressure in 2K1C is dependent of an im-
balance between high levels of ACE/Ang II and low
levels of ACE2/Ang 1–7, both being influenced by renin
activity [16,35]. In parallel, it has been reported that aug-
mentation of chymase activity in the ischemic kidney of
2K1C rats [36] may be a mechanism related with ACE-
independent intrarenal Ang II production. Moreover, previ-
ous studies have demonstrated that Ang II downregulatesFigure 8 Superoxide anion production in mesenteric vascular beds. T
using dihydroethidium (DHE), diaminofluorescein (DAF) and hydroxyphenyl fl
mice; the log fluorescence (X axis) illustrates the differences in intensity of fluo
production of superoxide anions and peroxynitrite in 2K1C hypertensive mice
values. On the other hand, 2K1C mice presented impairment of nitric oxide p
the normal levels. Values are median fluorescence intensity (MFI, in arbitrary uACE2 mRNA expression in some tissues, including the kid-
ney [37,38], which could be mediated by AT1 receptors
[39,40]. Based on the above findings and on our studies in
2K1C hypertensive mice, we speculate that the repair of the
stenotic kidney by sildenafil (administered for 14 days) was
mediated by attenuation of renal baroreceptor activity, with
consequent deactivation of the intrarenal RAS, as con-
firmed in the present study by decrease in intrarenal Ang I
(~33%) and II (~50%) and (contrasting) by increase in Ang
1–7 (~15%), as compared with 2K1C mice.
Regarding the plasma Ang I and II, our finding of nor-
malized levels at the chronic phase was expected based
on the fact that in the rat Ang-dependent renovascular
hypertension has been separated in two phases [5]. Theop panel shows representative histograms from flow cytometric analysis
uorescein (HPF) in Sham, 2K1C hypertensive and sildenafil-treated 2K1C
rescence for the number of cells counted. Bar graph shows augmented
compared with Sham mice and sildenafil treatment restored the normal
roduction compared with sham mice, and sildenafil treatment restored
nits) ± SEM for 5 animals per group. *p < 0.05 (one-way ANOVA).
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sion, which occurs from the first day following the place-
ment of the clip to the 14th day, when the plasma levels
of Ang II peak. The late (second) phase is related to the
maintenance of hypertension, which has been evaluated
at approximately 28 days after renal artery clipping, and
that shows stabilized plasma levels of Ang II [5]. In the
mouse model, the few available studies have reported an
increase in renin activity and the levels of Ang I (~50%)
[20,41], Ang II (~350%) [20,30,42] and Ang 1–7 in
plasma (~110%) [20] during the first phase of renovascu-
lar hypertension (14 days following the clip placement).
During the second phase of 2K1C hypertensive mice,
neither increased plasma renin activity nor elevated
levels of Ang I [41] or Ang II [42,43] has been detected,
justifying the similar profile founded in this study.
Altogether, the above data extend to the mice the time-
course profile of Ang that has been demonstrated by
Navar’s research group in the rat [5]. Surprisingly, we
observed that sildenafil treatment increased plasma
levels of Ang 1–7 (~45%), which is known to counter-
balance the deleterious effects elicited by Ang II [16,35].
Based on our findings, we speculate that the Ang 1–7
generated by the ACE2-mediated degradation of Ang II
may also limit the intrarenal uptake of Ang II, as dis-
cussed above. It should be noted that, in a review of
contemporary literature, it is notable a vast diversity in
the methods that have been used for the analysis of the
RAS in the few studies using the 2K1C mouse model,
confounding the comparison of the plasma and tissue
levels of RAS peptides. As a solution for this discrep-
ancy, we considered that it would be most appropriate
to compare our detected values in the hypertensive
2K1C mice and the 2K1C mice treated with sildenafil to
the average values in the Sham mice, which were nor-
malized to 100%; similarly, we will compare the data
found by us and others using relative (%) values.
In the present study, 2K1C mice exhibited a high BP,
approximately 20% higher than that of the Sham mice,
in agreement with other studies reporting similar in-
creases (20-25%) [12,15,30,31,41-45]. The high BP was
accompanied by tachycardia, which is consistent with
other reports [20,21,41]. As expected, and based on pre-
vious studies using the rat model [21,46-48], we found
that sildenafil normalized the BP and HR. Moreover, the
novelty of the present study is that according to the pro-
file of intrarenal and plasma Ang that we observed, it could
be speculated that these beneficial effects of sildenafil are
partially mediated by the reciprocal changes in Ang, i.e., a
decrease of Ang II and increase of Ang 1–7. This hypoth-
esis may be reinforced by the finding that chronic treat-
ment of spontaneously hypertensive rats (SHR) with Mas
receptor agonists or with Ang 1–7 led to vasorelaxation,
anti-hypertensive and cardioprotective effects [49,50].Additionally, the plasma levels of Ang 1-7 were increased
during treatment with ACE inhibitors or AT1 receptor
blockers, indicating a potential dependence of the anti-
hypertensive effects of those compounds on Ang 1–7
[18,39]. Despite of our results demonstrate a drop in Ang
II, we cannot rule out the possibility the participation of
AT2 receptor in this model of hypertension, since this
protein can stimulates NO signaling [51], potentiating the
effects of sildenafil. This hypothesis is corroborated by
other recent studies that demonstrated the importance of
AT2 receptor in renovascular hypertension [52,53]. Thus,
targeting the ACE2-Ang (1–7)-Mas and AT2 receptor axis
using new pharmacological tools, such as sildenafil, which
we used in the current study, may represent a novel thera-
peutic strategy for renovascular hypertension.
It has been demonstrated that the interruption of the
ACE2-Ang (1–7)-Mas axis is an underlying mechanism
responsible for the worsening of the developmental and
maintenance phases in 2K1C Mas knockout mice [39],
as well as impairing the baroreflex control, endothelial
function and the balance of NO/ROS in normotensive
mice [40,41]. In parallel, recent data have demonstrated
specific and beneficial effects of AT2 receptor via central
areas in hypertensive rats [54]. Considering the evidence
that sildenafil crosses the blood–brain barrier [55,56]
and that it affects the angiotensin profile, one cannot
rule out the possibility of also a central action on the
sympathetic/parasympathetic drive. In this context, al-
though recent studies have shown an increased sympa-
thetic drive imposed on the cardiovascular system by
sildenafil in both rats [56] and humans [57,58], we specu-
late that in our study (in which sildenafil was chronically
administered) its systemic antioxidant effects overtook the
possible undesirable sympathetic-mediated effects.
Endothelial dysfunction is an important abnormal func-
tion commonly observed in cardiovascular diseases, in-
cluding atherosclerosis [22] and various models of arterial
hypertension [15]. Previous studies by our group revealed
that the MAB exhibits an increased response to vasocon-
strictors and a decreased response to vasodilators in RAS-
dependent hypertensive rats [24,59] and mice [15]. Thus,
in the current study, we designed an experiment to evalu-
ate the effects of sildenafil treatment on endothelial dys-
function in hypertensive 2K1C mice. We selected the
2K1C model that was developed by Goldblatt decades ago
because endothelial dysfunction is an early characteristic
of RAS-dependent 2K1C-mediated hypertension [15,60].
As expected, ACh evoked endothelium-dependent relax-
ation, which was greatly diminished in the 2K1C mice.
However, no significant difference was detected in the
dose–response curve to the NO donor SNP, indicating
that vascular dysfunction may be due to dysfunctional mo-
lecular pathways in endothelial cells but not in vascular
smooth muscle cells. This result is in agreement with
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sorelaxation is associated with the second phase of chronic
2K1C hypertension in the rat model [5,61]. Because we
hypothesized that 2K1C-induced endothelial dysfunction
may be improved by chronic treatment with sildenafil,
standard experiments using pharmacological inhibitors
were designed to assess the relative contribution of each
molecular pathway to the relaxation responses to ACh in
the MAB and the effectiveness of sildenafil in restoring or
improving endothelial function in the 2K1C mice.
The relative importance of vasoactive substances, such as
NO, PGI2, EDHF and ROS, depends on the size of the
blood vessels and the experimental animal. Studies have
shown that in the rat, NO is the primary contributor to
ACh-induced vasodilation in the aorta, whereas EDHF
plays a predominant role in resistance vessels [62]. Our data
show that in both the wild type and hypertensive 2K1C
mice, the EDHF pathway was the primary contributor and
was scarcely altered in the endothelium-dependent relax-
ation response to ACh in the MAB. This finding corrobo-
rates a previous study showing that EDHF-mediated
dilatory responses were unaffected in mesenteric resistance
vessels in RAS-dependent hypertensive mice [63]. More-
over, our data show that in the vasodilator pathway, the im-
pairment of NO/cGMP was the primary contributor to
endothelial dysfunction, followed by PGI2, as determined
using hypertensive 2K1C mice. Indeed, the contribution of
NO and PGI2 to endothelial function in the 2K1C mice
was reduced to approximately 35% and 50%, respectively,
of that in the Sham mice. By blocking NAD(P)H using
apocynin, we also found that the levels of ROS, which have
opposing effects to those of NO and PGI2, were increased
approximately 6-fold in the 2K1C mice, in agreement with
the rat model of renovascular hypertension [48,64]. This
finding may be because high BP (enhanced shear stress)
and activation of the RAS have been shown to increase
ROS production by NAD(P)H oxidase via the AT1 receptor
axis, decreasing NO bioavailability in the 2K1C mice
[27,30,45,65]. The hypothesis that it occurs an imbalance
between NO and O2 levels in the endothelial cells isolated
from MAB, but not only systemically [21,30,31], was con-
firmed in a separated set of experiments by flow cytometry
in the present study. Additionally, by using the HPF stain-
ing, we found in renovascular hypertensive mice an in-
crease of endothelial production of peroxynitrite, which is
derived from the reaction of NO with the superoxide anion.
Taken together, these results suggest a relevant role of im-
pairments of the NOS/cGMP and prostanoid/cAMP path-
ways and the activation of the ROS/cGMP pathway in the
endothelial dysfunction observed in RAS-dependent hyper-
tension [66].
The second novel finding based on endothelial func-
tion analysis is that sildenafil recovered endothelial func-
tion to normal levels, as indicated by the parameters ofthe dose–response curve to ACh (Rmax and AUC) and
flow cytometry analysis of ROS. The recovery of endothe-
lial function by sildenafil treatment primarily occurred due
to a marked increase in the vasodilatory contribution of
NO and a marked decrease in the levels of superoxide and
(consequently) peroxynitrite anions. Recent data have
shown that this vasodilator effect of sildenafil may involve
indirect mechanisms, such as upregulation of BH4 and
soluble guanylate cyclase (sGC) enzyme, besides the inhib-
ition of NADPH oxidase activity, leading to the increase of
NO bioavailability [67]. These findings corroborate the no-
tion that the inhibition of PDE5 in the vessels in smooth
muscle directly enhances the NO/cGMP signaling path-
way by inhibiting cGMP degradation and subsequently
facilitating vessel relaxation [68].
Conclusion
In conclusion, our data show that the chronic treatment
of Ang-induced renovascular hypertensive mice with the
PDE5 inhibitor sildenafil leads to a decrease in high BP
and tachycardia, probably by decreasing the levels of
plasma and intrarenal Ang II and increasing the levels of
its physiological antagonist Ang 1–7. Additionally, sil-
denafil was able to abolish the endothelial dysfunction
and the increased production of •O2
− of resistance ves-
sels and then restoring the NO/ROS balance. The above
data and interpretation indicate that the activation of the
ACE2-Ang (1–7)-Mas axis by sildenafil may represent a
novel therapeutic target in the context of endothelial
dysfunction. Therefore, the present data revealing the
beneficial effects of sildenafil support the concept that
this inhibitor of PDE5 could be included in the hallmark
of anti-hypertensive agents currently available, especially
as an additional drug in patients with resistant hyperten-
sion despite the use of three or more drugs and in pa-
tients with endothelial dysfunction and kidney disease.
Limitations and perspectives
Although the present study was designed to assess the
functional beneficial effects of sildenafil, a limitation is that
our experiments did not completely elucidate the mecha-
nisms underlying the specific molecular pathways by
which sildenafil exerts its beneficial effects; we plan to ad-
dress this issue in further studies. However, this transla-
tional research is of clinical relevance because it reveals
new concept of interaction of sildenafil with the RAS and
opens the perspective of using sildenafil to stimulate the
production of Ang 1–7 as a new therapeutic approach for
the treatment of renovascular hypertension an endothelial
dysfunction, as well as for resistant hypertension.
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